{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-011072","form_type":"8-K","ticker":"AVR","cik":"0002011514","company_name":"Anteris Technologies Global Corp.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.792205+00:00","generated_at":"2026-05-24T02:35:20.277396+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anteris reaches 100 patients treated with DurAVR THV; strong one-year safety and efficacy data","bullets":["Over 100 patients treated with DurAVR THV, including de novo, valve-in-valve, and bicuspid cases.","65 patients completed 30-day primary endpoints; safety and efficacy demonstrated.","One-year data on 37 patients shows sustained large effective orifice areas and low mean pressure gradients.","No valve or cardiovascular mortality at one year; excellent safety profile.","Pivotal trial on track to commence Q3 2025, pending FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-011072","json":"https://secwatch.observer/filing/0001140361-25-011072.json","markdown":"https://secwatch.observer/filing/0001140361-25-011072.md","text":"https://secwatch.observer/filing/0001140361-25-011072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125011072/0001140361-25-011072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2011514/000114036125011072/ef20046399_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:35:20.277396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}